- HER2-overexpressing breast cancer:
- Extended adjuvant treatment of early-stage disease:
- PO 240mg OD for up to 1 year OR
- PO 120mg OD *1/52, then 160mg OD *1/52, then 240mg OD up to 1 year total as dose escalation regimen
- Start after adjuvant trastuzumab-based treatment
- Extended adjuvant treatment of early-stage disease:
-
- Recurrent metastatic disease for patients who have received 2 or more anti-HER2 based regimens:
- Days 1-21: PO 240mg OD PLUS days 1-14: capecitabine PO 750mg/m2 BD OR
- PO 240mg OD or 120mg OD *1/52, then 160mg OD *1/52, then 240mg OD as dose escalation regimen
- Recurrent metastatic disease for patients who have received 2 or more anti-HER2 based regimens:
Tablet: 40mg
- Antidiarrheal prophylaxis given for at least 1st 8 weeks of treatment if no dose escalation at treatment start
- To be taken with food at approximately the same time each day
Tyrosine Kinase Inhibitor
It binds irreversibly to tyrosine kinase domain of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), causing inhibition of ErbB signaling pathway and decreased tumor cell proliferation
- Diarrhea
- Nausea
- Abdominal pain
- Fatigue
- Vomiting
- Rash
- Stomatitis
- Decreased appetite
- Muscle spasms
- Dyspepsia
- Increased ALT/AST
- Nail disorder
- Xeroderma
- UTI
- Weight loss
- Epistaxis
- Dehydration
- Xerostomia
- Skin fissures
- Hypersensitivity to components
- Breastfeeding during treatment and for at least 1 month after discontinuation
None restricted
Drug Status
| Availability | Prescription only |
| Pregnancy | Contraindicated |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Hernix | 40mg | Tablet | 180’s | Beacon Medicare | Generics Africa |